Tipranks Press Release.
CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,150 restricted stock units (“RSUs”) to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable
Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.
Solid Biosciences is leveraging a differentiated SGT-003 gene therapy for Duchenne muscular dystrophy with a credible cash runway into mid-2028. Learn more about SLDB stock here.
Solid Biosciences' (SLDB) differentiated approach to Duchenne muscular dystrophy and a "materially d
Solid Biosciences (SLDB) has an average rating of buy and mean price target of $18.62, according to
CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2026 Cantor Global Healthcare ConferenceBo Cumbo, President and CEO, and Gabriel Books, M.D., Chief Medical Officer, will participate in a fireside chat on Wednesday, September 9, 2026, at 3:55 p.m. ET. A li
Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.